ERBB3
MOLECULAR TARGETerb-b2 receptor tyrosine kinase 3
ERBB3 (erb-b2 receptor tyrosine kinase 3) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting ERBB3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | erlotinib | 5.55 | 256 |
| 3 | osimertinib | 5.03 | 152 |
| 4 | lapatinib | 4.84 | 126 |
| 5 | alvocidib | 4.52 | 91 |
| 6 | foretinib | 4.34 | 76 |
| 7 | tozasertib | 4.33 | 75 |
| 8 | vandetanib | 4.30 | 73 |
| 9 | bosutinib | 4.08 | 58 |
| 10 | neratinib | 3.66 | 38 |
| 11 | canertinib | 3.53 | 33 |
| 12 | rociletinib | 3.18 | 23 |
| 13 | lestaurtinib | 3.04 | 20 |
| 14 | cediranib | 2.83 | 16 |
| 15 | canertinib dihydrochloride | 2.08 | 7 |
| 16 | sapitinib | 1.95 | 6 |
| 17 | Afatinib | 0.69 | 1 |
About ERBB3 as a Drug Target
ERBB3 (erb-b2 receptor tyrosine kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented ERBB3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
ERBB3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.